2020-11-16T20:45:24-05:00 2019-12-31 205732491 BRANDON ACCOUNTING SERVICES LLC 16905 GERMANTOWN ROAD Germantown MD 20874 990 2019-01-01 473290570 GLOBAL ALZHEIMERS PLATFORM FOUNDATION INC GLOB 1101 K STREET NW Washington DC 20005 JOHN DWYER PRESIDENT 3019809702 2020-11-14 true JAMES H BRANDON P00102973 3014522111 2020-11-16 74.220.81.79 2020-11-16 20:48:43 5226322020321dmuwku2 2020-11-16 P 701C5998661582E6113B3A72F60AB209FC616AE0 701C5998661582E6113B3A72F60AB209FC616AE0 2019 2021-01-29 14:40:06Z JOHN DWYER 4788807 false X www.globalalzplatform.org X 2015 DC TO JOIN TOGETHER LEADING ACADEMIC RESEARCHERS, PHARMACEUTICAL COMPANIES NONPROFIT ORGANIZATIONS, FOUNDATIONS AND GOVERNMENTS WORLDWIDE TO REDUCE TIME, COST AND RISK OF ALZHEIMERS CLINICAL TRIALS IN ORDER TO SPEED INNOVATIVE MEDICINES TO THOSE WITH OR AT RISK OF ALZHEIMERS 7 7 14 0 0 6427457 4788807 0 0 0 6427457 4788807 420000 505600 0 0 0 563093 4848944 6050464 5268944 6556064 1158513 -1767257 2529553 1436983 981209 1655896 1548344 -218913 TO JOIN TOGETHER LEADING ACADEMIC RESEARCHERS, PHARMACEUTICAL COMPANIES NONPROFIT ORGANIZATIONS, FOUNDATIONS AND GOVERNMENTS WORLDWIDE TO REDUCE TIME, COST AND RISK OF ALZHEIMERS CLINICAL TRIALS IN ORDER TO SPEED INNOVATIVE MEDICINES TO THOSE WITH OR AT RISK OF ALZHEIMERS false false 4026732 THE ORGANIZATION IS ESTABLISHING A STANDING GLOBAL TRIAL-READY PLATFORM TO DRIVE QUALITY, EFFICIENCY, AND INNOVATION IN ALZHEIMERS CLINICAL TRIALS, SEEKING TO REDUCE CLINICAL TESTING CYCLE TIMES BY TWO YEARS AND TO ACHIEVE GREATER UNIFORMITY IN TRIAL POPULATIONS. IT IS DOING THAT BY BUILDING LARGE, WELL-CHARACTERIZED TRIAL-READY COHORTS, AND A NETWORK OF CERTIFIED HIGH-PERFORMANCE CLINICAL TRIAL SITES. 4026732 true true false false false false false false false false true false false true false false false false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false true 0 0 14 true false false false false false false false false false false false false false false false false false X 7 7 false false false false false false false true true false false true true true true true true true true false X X THE ORGANIZATION 3014522111 1101 K STREET NW SUITE 400 Washington DC 20005 JOHN DWYER PRESIDENT AND CO-FOUNDER 40.00 0.00 X X 525983 0 0 GEORGE VRADENBURG BOARD CHAIR 20.00 0.00 X 0 0 0 STEVEN PAUL FOUNDING BOARD MEMBER 5.00 0.00 X 0 0 0 DREW HOLZAPFEL FOUNDING BOARD MEMBER 5.00 0.00 X 0 0 0 PASCALE WITZ BOARD MEMBER 5.00 0.00 X 0 0 0 NEIL BUCKHOLTZ BOARD MEMBER 5.00 0.00 X 0 0 0 MICHAEL J GLOSSERMAN BOARD MEMBER 5.00 0.00 X 0 0 0 525983 0 0 1 false true false RICHARD MOHS 1110 N LAKE SHORE DRIVE 19S CHICAGO IL 60611 CONSULTANT 204250 AMIDA TECHNOLOGY SOLUTIONS 1640 RHODE IS AVE NW 650 Washington DC 20036 WEB TECHNOLOGY 104018 RATIONAL 360 1828 L STREET NE 640 Washington DC 20036 PUBLIC RELATIONS 337740 PINTAIL SOLUTIONS LLC 40 CRICKETT KNOLL LA Carmel IN 46033 PROGRAM MGMT 1105165 4 4788807 4788807 4788807 0 0 0 X 505600 505600 3947944 2986634 525983 435327 127879 127879 146287 146287 571859 571859 247959 247959 1000 1000 11454 11454 DESIGN AND MARKETING 127766 127766 ADMINISTRATIVE SUPPORT 89885 89885 CONSULTANTS 243933 243933 534498 534498 6556064 4026732 1966239 563093 1840043 980133 604582 374219 5514 4217 4999 1488 4511 3511 74903 74903 2529553 1436983 277247 645896 505000 1010000 198962 981209 1655896 X 1548344 -218913 1548344 -218913 2529553 1436983 -1767257 0 X false true X true false X 3050000 4250341 6427457 4788807 18516605 3050000 4250341 6427457 4788807 18516605 8588008 9928597 14 14 18516619 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 4999 1488 3511 3511 TRADEMARKS 4950 WEB SITE 69953 74903 X X X false false false false false false false false false JOHN DWYER PRESIDENT AND CO-FOUNDER 430983 95000 525983 Form 990 governing body review Part VI line 11 THE FORM 990 WAS REVIEWED BY ONE OF THE DIRECTORS AND CHIEF EXECUTIVE OFFICER. A COPY WAS PROVIDED TO THE ORGANIZATIONS GOVERNING BODY BEFORE IT WAS FILED WITH THE IRS. Conflict of interest policy compliance Part VI line 12c EACH DIRECTOR, PRINCIPAL OFFICER AND MEMBER OF A COMMITTEE WITH GOVERNING BOARD DELEGATED POWERS ANNUALLY SIGNS A STATEMENT WHICH AFFIRMS THAT EACH HAS 1) RECEIVIED A COPY OF THE CONFLICTS OF INTEREST POLICY; 2) HAS READ AND UNDERSTANDS THE POLICY; 3) HAS AGREED TO COMPLY WITH THE POLICY; AND LASTLY, UNDERSTANDS THAT THE ORGANIZATION IS A NON-PROFIT PUBLIC BENEFIT CORPORATION AND, IN ORDER TO MAINTAIN ITS FEDERAL EXEMPTION, IT MUST ENGAGE PRIMARILY IN ACTIVITIES WHICH ACCOMPLISH ONE OR MORE OF ITS TAX-EXEMPT PURPOSES CEO executive director top management comp Part VI line 15a THE BOARD HAS A COMPENSATION COMMITTEE THAT MEETS TO REVIEW AND APPROVE COMPENSATION POLICIES AND COMPENSATION PLANS FOR OFFICERS. OFFICER COMPENSATION PLANS ARE REVIEWED AND COMPARED TO COMPARABLE MARKET DATA, ENVIRONMENTAL CONDITIONS AND OTHER IMPACTFUL CRITERIA. Other officer or key employee compensation Part VI line 15b THE BOARD HAS A COMPENSATION COMMITTEE THAT MEETS TO REVIEW AND APPROVE COMPENSATION POLICIES AND COMPENSATION PLANS FOR OFFICERS. OFFICER COMPENSATION PLANS ARE REVIEWED AND COMPARED TO COMPARABLE MARKET DATA, ENVIRONMENTAL CONDITIONS AND OTHER IMPACTFUL CRITERIA. Form 990 availability to public Part VI line 18 THE ORGANIZATION ALLOWS FOR NORMAL REVIEW OF ITS FORM 990 DURING NORMAL BUSINESS HOURS. Governing documents etc available to public Part VI line 19 THE ORGANIZATION MAKE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLCY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. List of other expenses Part IX line 24e REGISTRY INFORMATICS DATA MANAGEMENT 109,018PUBLIC RELATIONS 424,037RECRUITMENT MARKETING 1,443TOTAL OTHER PROGRAM SERVICE EXPENSE 534,498 General explanation attachment MISSION -TO JOIN TOGETHER LEADING ACADEMIC RESEARCHERS, PHARMACEUTICAL COMPANIES, NONPROFIT ORGANIZATIONS AND FOUNDATIONS, AND GOVERNMENTS AROUND THE WORLD TO REDUCE THE TIME, COST AND RISK OF ALZHEIMERS CLINICAL TRIALS IN ORDER TO SPEED INNOVATIVE MEDICINES TO THOSE WITH OR AT RISK OF ALZHEIMERS DISEASE.